Institute for Pharmacoeconomics and Drug Logistics, University of Wismar, Wismar, Germany.
Patient. 2009 Mar 1;2(1):39-49. doi: 10.2165/01312067-200902010-00005.
Since 2008, the availability of the oral direct thrombin inhibitor dabigatran etexilate provides a further therapeutic alternative to injectable low-molecular-weight heparin (LMWH) for thromboprophylaxis following hip or knee replacement surgery. The intention of this study is to analyze patient preferences for this new oral thromboprophylaxis agent.
Face-to-face interviews were conducted with 73 doctors and nurses in 12 German hospitals, 195 current hip and knee replacement patients in six German rehabilitation hospitals, and 202 former thromboprophylaxis patients. Qualitative questions were complemented by a full-profile ranking-based conjoint analysis regarding alternative thromboprophylaxis regimens.
Nearly 100% of the interviewed medical staff viewed the daily subcutaneous LMWH injection as a source of inconvenience for patients. However, both current and former patients perceived their discomfort to be much less intense. In contrast, the conjoint estimates of preferences showed that older and male patients in particular understated their levels of discomfort in a face-to-face interview situation and had a strong preference for oral anticoagulation.
Patients in Germany appear to have a positive preference for oral thromboprophylaxis after major orthopedic surgery.
自 2008 年以来,口服直接凝血酶抑制剂达比加群酯的出现为髋关节或膝关节置换术后的血栓预防提供了另一种治疗选择,可替代注射用低分子肝素(LMWH)。本研究旨在分析患者对这种新型口服抗血栓形成药物的偏好。
在德国 12 家医院对 73 名医生和护士进行了面对面访谈,在 6 家德国康复医院对 195 名现髋膝关节置换患者和 202 名既往抗血栓形成治疗患者进行了访谈。定性问题通过基于完整概况的偏好排序联合分析补充了替代抗血栓形成方案。
近 100%的接受访谈的医务人员认为每日皮下注射 LMWH 给患者带来了不便。然而,现患和既往患者都认为他们的不适程度要低得多。相比之下,偏好的联合估计显示,特别是老年和男性患者在面对面访谈情境中低估了他们的不适程度,并强烈偏好口服抗凝治疗。
德国的患者似乎对骨科大手术后的口服抗血栓形成治疗有积极的偏好。